Abstract

Volume.128 Number.4

Original article : Clinical science

Advanced Medical Care Using Gene Panel Testing: Genetic Testing for Inherited Retinal Dystrophy
Akiko Maeda1,2, Satoshi Yokota1,2, Yusaku Urakawa1,2, Akiko Yoshida1, Akira Inaba1, Kanako Kawai1, Mitsuhiro Matsuzaki1,2, Daiki Sakai1,2, Kazuya Tayasu1, Miyuki Koba1, Midori Yamamoto1, Naohiro Motozawa1, Shohei Kitahata1, Tadao Maeda1, Michiko Mandai1, Haruka Murakami4, Satomi Inoue4, Natsuko Nakamura1,3, Kaoru Fujinami3,4, Kazuki Yamazawa4, Kazushige Tsunoda3, Naoya Morisada5, Yasuhiko Hirami1,2, Yasuo Kurimoto1,2, Masayo Takahashi1,6
1 Kobe City Eye Hospital
2 Department of Ophthalmology, Kobe City Medical Center General Hospital
3 Department of Ophthalmology, National Hospital Organization Tokyo Medical Center
4 Department of Clinical Genetics, National Hospital Organization Tokyo Medical Center
5 Department of Clinical Genetics, Hyogo Prefectural Kobe Children's Hospital
6 Vision Care Inc.

Purpose: Gene-specific treatment of inherited retinal dystrophy (IRD) is under development and identification of the causative genes for the condition is helpful for selecting treatment options in the future. Additionally, determining the inheritance pattern by identifying the causative gene provides useful information for patients and their family members. This study examined the usefulness of the clinical flow by performing comprehensive gene panel testing, an advanced medical care, and providing the results.
Subjects and methods: Genetic counseling was provided to 101 patients with IRD at two facilities in Japan, and blood was collected from 100 patients who requested genetic testing. We extracted DNA from the blood samples and analyzed 82 disease-causing genes. The analysis results and the patients' clinical symptoms were examined by an expert panel, with the aim of proposing a treatment plan including identification of the causative gene and low vision care.
Results: The identification rate of the causative gene was 41.0%, and the rate increased to 55.0% when the cases of variant of unknown significance according to the American College of Medical Genetics and Genomics (ACMG) guidelines were included on the suggestion from the expert panel. Patient satisfaction with genetic counseling was high (98.0% and 96.0%, before test and after results disclosure, respectively), and 32 of 80 patients (40%) were able to access low vision care one year after the results were disclosed.
Conclusion: The present study suggests the usefulness of this clinical flow.
Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 128: 305-310,2024.

Key words
Inherited retinal dystrophy (IRD), Advanced medical care, Genetic testing, Genetic counseling, Low vision care
Reprint requests to
Akiko Maeda M. D., Ph. D. Kobe City Eye Hospital. Minatojima-minamimachi, Chuo-ku, Kobe-shi 2-1-8, 650-0047, Japan